Search results
-
ASCO 2024 – Summit peaks on ivonescimab surprise
ASCO 2024 – Summit peaks on ivonescimab surprise … OS Immature 21.1mth 19.2mth Source: ASCO 2024 & OncologyPipeline. Overall survival …
- 06/02/2024 - 15:03 -
ASCO 2024 – J&J flies towards a more convenient Rybrevant
ASCO 2024 – J&J flies towards a more convenient Rybrevant … non-inferiority criteria; **trend in favour of SC. Source: ASCO 2024. When asked for a potential explanation …
- 06/01/2024 - 01:41 -
ASCO 2024 – Scemblix could set new standard in front-line leukaemia
ASCO 2024 – Scemblix could set new standard in front-line …
- 10/31/2024 - 15:19 -
ASCO 2024 preview – conjugates in focus
ASCO 2024 preview – conjugates in focus … molecules. Selected ADCs being presented at ASCO 2024 Project Target Payload Company …
- 05/31/2024 - 20:48 -
ASCO 2024 preview – with more patients Merus claims better efficacy
ASCO 2024 preview – with more patients Merus claims better …
- 05/29/2024 - 16:17 -
Verastem spoils its ASCO bounce
… patients as well as those with KRAS-mutant disease. ASCO 2024 In mid-2020 Verastem bought avutometinib, a …
- 05/29/2024 - 13:14 -
ASCO 2024 abstract movers – Merus convinces, at first
ASCO 2024 abstract movers – Merus convinces, at first …
- 05/29/2024 - 14:20 -
ASCO 2024 preview – toxicity looms large for J&J
ASCO 2024 preview – toxicity looms large for J&J …
- 05/24/2024 - 15:51 -
ASCO 2024 preview – more questions for BioNTech
ASCO 2024 preview – more questions for BioNTech … 33% Note: cutoff date 9 January 2024. Source: ASCO 2024 abstract. This could come at a cost, … 63% Note: cutoff date 20 December 2023. Source: ASCO 2024 abstract. In the second line, results …
- 05/23/2024 - 22:58 -
ASCO 2024 preview – Merus’s home run remains unconfirmed
ASCO 2024 preview – Merus’s home run remains unconfirmed …
- 05/23/2024 - 23:02
